Hormone replacement therapy and thrombotic risk: Effects on haemostasis, and the risk of venous thromboembolism

HAEMA

Volumn 6, Issue 2, 2003, Pages 166-175

  Spiliotopoulou, Ioanna ^a   Grouzi, Elissavet ^a  

^a KAT HOSPITAL   (Greece)

Author keywords

Estrogens; Hormone replacement therapy; Ischemic heart disease; Progestogens; Venous thromboembolism

Indexed keywords

APOLIPOPROTEIN E; CONJUGATED ESTROGEN; ESTROGEN; GENISTEIN; GESTAGEN; PHYTOESTROGEN; RALOXIFENE; TAMOXIFEN; TIBOLONE;

ALZHEIMER DISEASE; BREAST CANCER; CANCER RISK; DRUG EFFECT; FRACTURE; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; LIPID BLOOD LEVEL; REVIEW; THROMBOEMBOLISM; THROMBOSIS;

EID: 0037498425     PISSN: 11082682     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. American College of Physicians. Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med 1992; 117: 1038-1041.
2. Mendelshon ME, Karas RH. The protective effects of estrogen on cardiovascular system. N Engl J Med 1999; 340: 1801-1811.
3. Harris ST, Genant HK, Baylink DJ et al. The effects of estrogen (Ogen) on spinal bone density of postmenopausal women. Arch Intern Med 1991; 151: 1980-1984.
4. Prelevin GM, Jacobs HS. Menopause and postmenopause. Baillière's Clin Endocrinol Metab 1997; 11: 311-340.
5. Grady D, Rubin SM, Petitti DB et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-1037.
6. Goldstein F, Stampfer MJ, Colditz GA et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769-1775.
7. Messerli FH, Caravaglia GE, Schimieder RE et al. Disparate cardiovascular finding in men and woman with essential hypertension. Ann Inter Med 1987; 107: 158-161.
8. Hullery S, Grady D, Bush T et al for the Heart and estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-613.
9. Matthews KA, Meilahn E, Kuller LH et al. Menopause and risk factors for coronary artery disease. N Engl J Med 1989; 321: 641-646.
10. Sacks FM, Walsh BW. The effects of reproductive hormones on serum lipoproteins: unresolved issues in biology and clinical practice. Ann NY Acad Sci 1990; 592: 272-285.
11. Walsh JME, Grady D. Treatment of hyperlipidemia in women. JAMA 1995; 274: 1152-1158.
12. Sacks FM, McPherson R, Walsh BW. Effect of postmenopausal estrogen replacement on plasma Lpa. Lipo-protein concentrations. Arch Intern Med 1994; 154: 1106-1110.
13. Sack MN, Rader DJ, Cannon RO. Oestrogen and inhibition of oxidation of low-density lipoprotein in postmenopausal women. Lancet 1994; 343: 269-270.
14. Ross D, Whitehead MI. Selecting patients for HRT: Positive indications. Br J Clin Pract 1995; 49: 92-94.
15. Julkunen H. Hormone replacement therapy in women with rheumatic diseases. Scand J Rheumatol 2000; 29: 146-153.
16. Fogelman I. The effects of oestrogen deficiency on the skeleton and its prevention. Br J Obstet Gynecol 1996; 103(suppl. 14): 5-9.
17. Crawshaw A. Carcinoma of the breast and hormone replacement therapy for osteoporosis. Int J Clin Pract 2000; 54: 99-103.
18. Waselenco JK, Nace WC, Alving B. Women with thrombophilia: assessing the risks for thrombosis with oral contraceptives or hormone replacement therapy. Semin Thromb Hemost 1998; 24(suppl. 1): 33-40.
19. Rice MM, Graves AB, McCarry SM, Larson EB. Estrogen replacement therapy and cognitive function in postmenopausal women without dementia. Am J Med 1997; 103: 26S-35S.
20. Birge SJ, Mortel KF. Estrogen and the treatment of Alzheimer's disease. Am J Med 1997; 103: 36S-45S.
21. Schneider LS, Farlow MR, Pogoda JM. Potential role of estrogen replacement therapy in the treatment of Alzheimer's disease. Am J Med 1997; 103: 46S-50S.
22. Yaffe K, Savwaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998; 279: 688-695.
23. Henderson VW. Estrogen, cognition, and a woman's risk of Alzheimer's disease. Am J Med 1997; 103: 11S-18S.
24. Dixon JM. Hormone replacement therapy and the breast. BMJ 2001; 323: 1381-1382.
25. Schairer C, Lubin J, Troisi R et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283: 485-491.
26. Anonymous. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions trial (PEPI). The Working Group for the PEPI trial. JAMA 1996; 275: 370-375.
27. Grady D, Gebretsadik T, Kerlikowske K et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995; 85: 304-313.
28. Grodstein F, Newcomb AP, Stampfer MJ. Postmenopausal Hormone Replacement Therapy and the risk of Colorectal Cancer: a review and meta-analysis. Am J Med 1999; 16: 574-582.
29. Scarabin PY, Bomithon-Knopp C, Bara L et al. FVII activation and menopause status. Thromb Res 1990; 57: 227-234.
30. Meade TW, Dyer S, Howarth DJ et al. Antithrombin III and procoagulant activity: sex differences and effect of the menopause. Br J Haematol 1990; 74: 77-81.
31. Scarabin PY, Plu-Bureau G, Bara L et al. Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thromb Haemost 1993; 70: 584-587.
32. Meade TW, Ruddock V, Stirling Y et al. Fibrinolytic activity, clotting factors, and long term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-1079.
33. Daly E, Vessey MP, Hawkins MM et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-980.
34. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal estrogens. Lancet 1996; 348: 981-983.
35. Perez Gutthann SP, Garcia Rodriguez LA, Castellsague J, Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism: population bazed case control study. BMJ 1997; 314: 796-800.
36. Report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. Surgically confirmed gallbladder, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. N Engl J Med 1974; 290: 15-19.
37. Pettiti DB, Wingerd J, Pellegrin F, Ramcharan S. Risk of vascular disease in women. Smoking, oral contraceptives, noncontraceptive estrogens, and other factors. JAMA 1979; 242: 1150-1154.
38. Hammond CB, Jelovsek FR, Lee KL et al. Effects of long-term estrogen replacement therapy. I. Metabolic effects. Am J Obstet Gynecol 1979; 133: 525-536.
39. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy. II. A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979; 54: 74-79.
40. Grodstein F, Stampfer MJ, Goldhaber SZ et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-987.
41. Hoibraaten E, Abdelnoor M, Sandset PM. Hormone replacement therapy with oestradiol and the risk of venous thromboembolism: a population-based case-control study. Thromb Haemost 1999; 82: 1218-1221.
42. Grady D, Wenger NK, Herrington D et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. Ann Intern Med 2000; 132; 689-696.
43. Varas Lorenzo C, Garcia Rodriguez LA, Cattaruzzi C et al. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in Southern Europe. Am J Epidemiol 1998; 147: 387-390.
44. Hoibraaten E, Qvigstad E, Arnesen H et al. Increased risk of recurrent venous thromboembolism during hormone replacement therapy; results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000; 84: 961-967.
45. Lowe G, Woodward M, Vessey M et al. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years: relationships to hormone replacement therapy. Thromb Haemost 2000; 83: 530-535.
46. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Oral contraceptives, Hormone replacement therapy and Thrombosis. Thromb Haemost 2001; 86: 112-123.
47. Psaty BM, Smith NL, Lemaitre RN et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 2001; 285: 906-913.
48. Rosendaal FR, Vessey M, Ramley A et al. Hormone replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 2002; 116: 851-854.
49. Chae CU, Ridker PM, Manson JE. Postmenopausal hormone replacement therapy and cardiovascular disease. Thromb Haemost 1997; 78: 770-780.
50. Kroon UB, Silfverstolpe G, Tengborn I. The effects of transdermal estradiol and oral conjugated estrogen on haemostasis variables. Thromb Haemost 1994; 71: 420-423.
51. Scarabin PY, Althenc-Gelas M, Plu-Bureau G et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Atheroscler Thromb Vasc Biol 1997; 17: 3071-3078.
52. Conard J, Gompel A, Pelissier C et al. Fibrinogen and plasminogen modifications during oral estradiol replacement therapy. Fertil Steril 1997; 68: 449-453.
53. The Writing Group for the Estradiol Clotting Factors Study. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study. Thromb Haemost 1996; 75: 476-480.
54. Lip GY, Blann AD, Jonew AF, Beevers DG. Effects of hormone replacement therapy on haemostatic factors, lipid factors and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. Am Heart J 1997; 134: 764-771.
55. Nabulsi AA, Folsom AR, White A et al. for the Atherosclerosis Risk in Communities Study Investigators. Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328: 1069-1075.
56. Lee AJ, Lowe GOD, Smith WCS, Turnstall-Pedoe H. Plasma fibrinogen in women; relationships with oral contraception, the menopause and hormone replacement therapy. Br J Haematol 1993; 83: 612-621.
57. Folsom AR, Wu KK, Davis CE et al. Population correlates of plasma fibrinogen and factor VII, putative cardiac risk factors. Atherosclerosis 1991; 91: 191-205.
58. Meinlahn EN, Kuller LH, Matthews KA, Kiss JE. Haemostatic factors according to menopausal status and use of hormone replacement therapy. Ann Epidemiol 1992; 2: 445-455.
59. Scarabin PY, Vissac AM, Kirtzin JM et al. Population correlates of coagulation factor VII: importance of age, sex, and menopausal status as determinants of activated FVII. Atheroscler Thromb Vasc Biol 1996; 16: 1170-1176.
60. Caine YG, Bauer KA, Barzegar S et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 1992; 68: 392-395.
61. Gottsater A, Rendell M, Hulthen UL et al. Hormone replacement therapy in healthy postmenopausal women: A randomized placebo-controlled study of effects on coagulation and fibrinolysis factors. J Intern Med 2001; 249: 237-246.
62. Douketis JD, Gordon M, Johnston M et al. The effects of hormone replacement on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: prospective cohort study and review of literature. Thromb Res 2000; 99: 25-34.
63. Gebara OCE, Mittleman MA, Sutherland P et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995; 91: 1952-1958.
64. Shahar E, Folsom AR, Salomaa VV et al. Relation of hormone replacement therapy on measures of plasma fibrinolytic activity. Circulation 1996; 93: 1970-1975.
65. Gilabert J, Estelles A, Cano A et al. The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic and coagulation inhibitors in postmenopausal status. Am J Obstet Gynecol 1995; 173: 1849-1854.
66. Koh KK, Horne MK, Csako G et al. Relation of fibrinolytic potentiation by estrogen to coagulation pathway activation in postmenopausal women. Am J Cardiol 1999; 83: 466-469.
67. Kho KK, Mincemoyer R, Bui MN et al. Effects of hormone replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336: 683-690.
68. Lip GY, Felmeden DC. Hormone replacement therapy and cardiovascular risk: do abnormalities of coagulation and fibrinolysis matter? J Intern Med 2001; 249: 201-204.
69. Aune B, Oian P, Omsjo I, Osterud B. Hormone replacement therapy reduces the reactivity of monocytes and platelets in whole blood. A beneficial effect on atherogenesis and thrombus formation? Am J Obstet Gynecol 1995; 173: 1816-1820.
70. Bar J, Tepper R, Fuchs J et al. The effects of estrogen replacement therapy on platelet aggregation and adenosine triphosphate release in postmenopausal women. Obstet Gynecol 1993; 81: 261-264.
71. Rozenberg S, Kroll M, Vandromme J. Decision factors influencing hormone replacement therapy. Br J Obstet Gynecol 1996; 103: 92-98.
72. Pritchars KI, Parerson AHG, Pual NA et al. for the National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol 1996; 14: 2731-2737.
73. Walsh BW, Kuller LH, Wild RA et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279: 145-151.
74. Davis SR. Phytoestrogen therapy for menopausal symptoms? BMJ 2001; 323: 354-355.
75. Clarkson TB, Anthony MS, Morgan FJ. Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J Clin Endocrinol Metab 2001; 86: 41-47.
76. Sturdee DW. Current hormone replacement therapy: what are the shortcomings? Advances in delivery. Int J Clin Path 1999; 53: 468-472.
77. Studd J, Arnala I, Kicovic PM et al. A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. Obstet Gynecol 1998; 92: 574-579.